Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

NCT06686108 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

T-cell Acute Lymphoblastic Leukemia
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Relapse

Interventions

DRUG: Azacitidine (AZA) Days 1 - 5
DRUG: Decitabine (DAC)
DRUG: Venetoclax

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine